Pfizer Limited reported a strong Q2 performance with a net profit of Rs 313.25 crore, boosted by a Rs 132.06 crore exceptional gain from the discontinuation of its 'Minipress XL' product line. While operational revenue grew to Rs 726.86 crore, investors should note this one-time gain when assessing long-term profit sustainability.
Pfizer Ltd Q2 Profit Climbs to Rs 313.25 Crore
Revenue from operations reached Rs 726.86 crore for the quarter; net profit includes a Rs 132.06 crore exceptional gain.
Reader Takeaway: Revenue shows steady core growth, but the bottom line is inflated by a one-time product discontinuation settlement.
What just happened
Pfizer Limited reported its financial results for the quarter ended September 30, 2026, showing significant growth in both top and bottom-line metrics compared to the previous year. The results include a one-time exceptional gain of Rs 132.06 crore (net of expenses) following the decision to discontinue the marketing and sale of the drug 'Minipress XL'. This decision was mandated by the parent company, Pfizer Inc. USA, and became effective on September 7, 2026.
Why this matters
The jump in net profit to Rs 313.25 crore—up from Rs 189.02 crore in the same quarter last year—is largely attributable to the lump sum payment received for the product exit. Investors analyzing the company's valuation must differentiate between this non-recurring windfall and the company's core pharmaceutical business performance. While the underlying revenue of Rs 726.86 crore reflects healthy growth from Rs 642.34 crore in Q2 FY26, the exceptional item masks the underlying operational margin trends.
Context metrics (time-bound)
- Revenue (H1 FY27): Rs 1,380.03 crore versus Rs 1,245.39 crore in H1 FY26.
- Net Profit (H1 FY27): Rs 517.72 crore versus Rs 380.77 crore in H1 FY26.
- Basic EPS (Q2 FY27): Rs 68.47 versus Rs 41.32 in Q2 FY26.
What to track next
Market observers will look for management commentary regarding the impact of the 'Minipress XL' discontinuation on future revenue streams. Additionally, shareholders should monitor whether the company maintains its recent dividend payout trend, following the Rs 75 per share dividend distributed earlier this financial year.